Review



camkii inhibitor ra306  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress camkii inhibitor ra306
    Serine/threonine protein kinases regulating PEAK3 S69 phosphorylation. A , consensus motifs of serine/threonine protein kinases with selectivity corresponding to the PEAK3 S69 region. Phosphorylation sites (position 0) are highlighted in pink and key features highlighted are arginine or lysine at position −3 ( orange ) and hydrophobic residues (ϕ) at +1 and −5 position ( blue ). X = any amino acid. Motifs sourced from Johnson et al. and PhosphoSitePlus ( , ). B , role of PKCs. MCF-10A/PEAK3 cells were treated with Go6850 or Go6976 and cell lysates subjected to Western blotting as indicated. Results are representative of four independent experiments. Histogram indicates the relative level of PEAK3 p-S69 normalized for HA and expressed relative to the DMSO control, which was arbitrarily set to 1.0. Data represent mean ± S.E.M., with 'au' indicating arbitrary units. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test. C , role of CaMKII as determined by pharmacological inhibition. MCF-10A/PEAK3 cells were treated with <t>RA306</t> or vehicle control and cell lysates analyzed by Western blotting as indicated. Data are representative of three independent experiments. Results in C are derived from the same experiment and use the same DMSO control. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M., ∗∗ p < 0.01, by ratio paired t test. D , role of CaMKII as determined by knockdown. CaMKIID and G were subject to siRNA-mediated knockdown (KD) in MCF-10A/PEAK3 cells and PEAK3 p-S69 assayed by Western blotting as indicated. Data are representative of three independent experiments. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M. over three independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test.
    Camkii Inhibitor Ra306, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/camkii+inhibitor+ra306/CaMKII+alpha+Antibody/pmc13089168-289-27-57
    Average 94 stars, based on 13 article reviews
    camkii inhibitor ra306 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "A tandem recruitment site in the pseudokinase scaffold PEAK3 is subject to phosphorylation-dependent regulation and cancer-associated mutations"

    Article Title: A tandem recruitment site in the pseudokinase scaffold PEAK3 is subject to phosphorylation-dependent regulation and cancer-associated mutations

    Journal: The Journal of Biological Chemistry

    doi: 10.1016/j.jbc.2026.111365

    Serine/threonine protein kinases regulating PEAK3 S69 phosphorylation. A , consensus motifs of serine/threonine protein kinases with selectivity corresponding to the PEAK3 S69 region. Phosphorylation sites (position 0) are highlighted in pink and key features highlighted are arginine or lysine at position −3 ( orange ) and hydrophobic residues (ϕ) at +1 and −5 position ( blue ). X = any amino acid. Motifs sourced from Johnson et al. and PhosphoSitePlus ( , ). B , role of PKCs. MCF-10A/PEAK3 cells were treated with Go6850 or Go6976 and cell lysates subjected to Western blotting as indicated. Results are representative of four independent experiments. Histogram indicates the relative level of PEAK3 p-S69 normalized for HA and expressed relative to the DMSO control, which was arbitrarily set to 1.0. Data represent mean ± S.E.M., with 'au' indicating arbitrary units. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test. C , role of CaMKII as determined by pharmacological inhibition. MCF-10A/PEAK3 cells were treated with RA306 or vehicle control and cell lysates analyzed by Western blotting as indicated. Data are representative of three independent experiments. Results in C are derived from the same experiment and use the same DMSO control. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M., ∗∗ p < 0.01, by ratio paired t test. D , role of CaMKII as determined by knockdown. CaMKIID and G were subject to siRNA-mediated knockdown (KD) in MCF-10A/PEAK3 cells and PEAK3 p-S69 assayed by Western blotting as indicated. Data are representative of three independent experiments. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M. over three independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test.
    Figure Legend Snippet: Serine/threonine protein kinases regulating PEAK3 S69 phosphorylation. A , consensus motifs of serine/threonine protein kinases with selectivity corresponding to the PEAK3 S69 region. Phosphorylation sites (position 0) are highlighted in pink and key features highlighted are arginine or lysine at position −3 ( orange ) and hydrophobic residues (ϕ) at +1 and −5 position ( blue ). X = any amino acid. Motifs sourced from Johnson et al. and PhosphoSitePlus ( , ). B , role of PKCs. MCF-10A/PEAK3 cells were treated with Go6850 or Go6976 and cell lysates subjected to Western blotting as indicated. Results are representative of four independent experiments. Histogram indicates the relative level of PEAK3 p-S69 normalized for HA and expressed relative to the DMSO control, which was arbitrarily set to 1.0. Data represent mean ± S.E.M., with 'au' indicating arbitrary units. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test. C , role of CaMKII as determined by pharmacological inhibition. MCF-10A/PEAK3 cells were treated with RA306 or vehicle control and cell lysates analyzed by Western blotting as indicated. Data are representative of three independent experiments. Results in C are derived from the same experiment and use the same DMSO control. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M., ∗∗ p < 0.01, by ratio paired t test. D , role of CaMKII as determined by knockdown. CaMKIID and G were subject to siRNA-mediated knockdown (KD) in MCF-10A/PEAK3 cells and PEAK3 p-S69 assayed by Western blotting as indicated. Data are representative of three independent experiments. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M. over three independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test.

    Techniques Used: Phospho-proteomics, Western Blot, Control, Inhibition, Derivative Assay, Knockdown

    Related Articles

    Recombinant:

    Article Title: A tandem recruitment site in the pseudokinase scaffold PEAK3 is subject to phosphorylation-dependent regulation and cancer-associated mutations
    Article Snippet: Goat anti-rabbit IgG (H+L) secondary antibody conjugated to Alexa Fluor 555 (A-21428) was from ThermoFisher Scientific. .. The following reagents/inhibitors were used in this study: lambda protein phosphatase (New England Biolabs, P0753S), animal-free recombinant human EGF (PeproTech, AF-100–15), insulin from bovine pancreas (Merck, I-1882), CaMKII inhibitor RA306 (custom synthesized by Reagency, RGNCY-0117, 1 μM final), PKA Inhibitor 14 to 22 Amide, Cell-Permeable, Myristoylated (Calbiochem, 476,485, 10 μM final), DMSO (Sigma, d8418, 0.1% final), and MedChemExpress-sourced Akt inhibitor MK-2206 dihydrochloride (HY-10358, 100 nM final) and trametinib (HY-10999, 10 nM final). .. PKC inhibitor Go6850 (S7208, 10 μM final) and Go6976 (S7119, 5 μM final), Pan PI3K inhibitor BKM120 (also known as Buparlisib/NVP-BKM120, S2247, 500 nM final), ROCK inhibitor (Y-27632, 10 μM final), and PKD inhibitor CRT0066101 dihydrochloride (S8366, 10 μM final) were purchased from Selleck Chemicals.

    Synthesized:

    Article Title: A tandem recruitment site in the pseudokinase scaffold PEAK3 is subject to phosphorylation-dependent regulation and cancer-associated mutations
    Article Snippet: Goat anti-rabbit IgG (H+L) secondary antibody conjugated to Alexa Fluor 555 (A-21428) was from ThermoFisher Scientific. .. The following reagents/inhibitors were used in this study: lambda protein phosphatase (New England Biolabs, P0753S), animal-free recombinant human EGF (PeproTech, AF-100–15), insulin from bovine pancreas (Merck, I-1882), CaMKII inhibitor RA306 (custom synthesized by Reagency, RGNCY-0117, 1 μM final), PKA Inhibitor 14 to 22 Amide, Cell-Permeable, Myristoylated (Calbiochem, 476,485, 10 μM final), DMSO (Sigma, d8418, 0.1% final), and MedChemExpress-sourced Akt inhibitor MK-2206 dihydrochloride (HY-10358, 100 nM final) and trametinib (HY-10999, 10 nM final). .. PKC inhibitor Go6850 (S7208, 10 μM final) and Go6976 (S7119, 5 μM final), Pan PI3K inhibitor BKM120 (also known as Buparlisib/NVP-BKM120, S2247, 500 nM final), ROCK inhibitor (Y-27632, 10 μM final), and PKD inhibitor CRT0066101 dihydrochloride (S8366, 10 μM final) were purchased from Selleck Chemicals.



    Similar Products

    camkii inhibitor ra306  (MedChemExpress)
    94
    MedChemExpress camkii inhibitor ra306
    Serine/threonine protein kinases regulating PEAK3 S69 phosphorylation. A , consensus motifs of serine/threonine protein kinases with selectivity corresponding to the PEAK3 S69 region. Phosphorylation sites (position 0) are highlighted in pink and key features highlighted are arginine or lysine at position −3 ( orange ) and hydrophobic residues (ϕ) at +1 and −5 position ( blue ). X = any amino acid. Motifs sourced from Johnson et al. and PhosphoSitePlus ( , ). B , role of PKCs. MCF-10A/PEAK3 cells were treated with Go6850 or Go6976 and cell lysates subjected to Western blotting as indicated. Results are representative of four independent experiments. Histogram indicates the relative level of PEAK3 p-S69 normalized for HA and expressed relative to the DMSO control, which was arbitrarily set to 1.0. Data represent mean ± S.E.M., with 'au' indicating arbitrary units. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test. C , role of CaMKII as determined by pharmacological inhibition. MCF-10A/PEAK3 cells were treated with <t>RA306</t> or vehicle control and cell lysates analyzed by Western blotting as indicated. Data are representative of three independent experiments. Results in C are derived from the same experiment and use the same DMSO control. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M., ∗∗ p < 0.01, by ratio paired t test. D , role of CaMKII as determined by knockdown. CaMKIID and G were subject to siRNA-mediated knockdown (KD) in MCF-10A/PEAK3 cells and PEAK3 p-S69 assayed by Western blotting as indicated. Data are representative of three independent experiments. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M. over three independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test.
    Camkii Inhibitor Ra306, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/camkii+inhibitor+ra306/CaMKII+alpha+Antibody/pmc13089168-289-27-57
    Average 94 stars, based on 1 article reviews
    camkii inhibitor ra306 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Serine/threonine protein kinases regulating PEAK3 S69 phosphorylation. A , consensus motifs of serine/threonine protein kinases with selectivity corresponding to the PEAK3 S69 region. Phosphorylation sites (position 0) are highlighted in pink and key features highlighted are arginine or lysine at position −3 ( orange ) and hydrophobic residues (ϕ) at +1 and −5 position ( blue ). X = any amino acid. Motifs sourced from Johnson et al. and PhosphoSitePlus ( , ). B , role of PKCs. MCF-10A/PEAK3 cells were treated with Go6850 or Go6976 and cell lysates subjected to Western blotting as indicated. Results are representative of four independent experiments. Histogram indicates the relative level of PEAK3 p-S69 normalized for HA and expressed relative to the DMSO control, which was arbitrarily set to 1.0. Data represent mean ± S.E.M., with 'au' indicating arbitrary units. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test. C , role of CaMKII as determined by pharmacological inhibition. MCF-10A/PEAK3 cells were treated with RA306 or vehicle control and cell lysates analyzed by Western blotting as indicated. Data are representative of three independent experiments. Results in C are derived from the same experiment and use the same DMSO control. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M., ∗∗ p < 0.01, by ratio paired t test. D , role of CaMKII as determined by knockdown. CaMKIID and G were subject to siRNA-mediated knockdown (KD) in MCF-10A/PEAK3 cells and PEAK3 p-S69 assayed by Western blotting as indicated. Data are representative of three independent experiments. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M. over three independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test.

    Journal: The Journal of Biological Chemistry

    Article Title: A tandem recruitment site in the pseudokinase scaffold PEAK3 is subject to phosphorylation-dependent regulation and cancer-associated mutations

    doi: 10.1016/j.jbc.2026.111365

    Figure Lengend Snippet: Serine/threonine protein kinases regulating PEAK3 S69 phosphorylation. A , consensus motifs of serine/threonine protein kinases with selectivity corresponding to the PEAK3 S69 region. Phosphorylation sites (position 0) are highlighted in pink and key features highlighted are arginine or lysine at position −3 ( orange ) and hydrophobic residues (ϕ) at +1 and −5 position ( blue ). X = any amino acid. Motifs sourced from Johnson et al. and PhosphoSitePlus ( , ). B , role of PKCs. MCF-10A/PEAK3 cells were treated with Go6850 or Go6976 and cell lysates subjected to Western blotting as indicated. Results are representative of four independent experiments. Histogram indicates the relative level of PEAK3 p-S69 normalized for HA and expressed relative to the DMSO control, which was arbitrarily set to 1.0. Data represent mean ± S.E.M., with 'au' indicating arbitrary units. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test. C , role of CaMKII as determined by pharmacological inhibition. MCF-10A/PEAK3 cells were treated with RA306 or vehicle control and cell lysates analyzed by Western blotting as indicated. Data are representative of three independent experiments. Results in C are derived from the same experiment and use the same DMSO control. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M., ∗∗ p < 0.01, by ratio paired t test. D , role of CaMKII as determined by knockdown. CaMKIID and G were subject to siRNA-mediated knockdown (KD) in MCF-10A/PEAK3 cells and PEAK3 p-S69 assayed by Western blotting as indicated. Data are representative of three independent experiments. Histogram indicates the relative level of PEAK3 p-S69 as mean ± S.E.M. over three independent experiments. ∗ p < 0.05, ∗∗ p < 0.01, by ratio paired t test.

    Article Snippet: The following reagents/inhibitors were used in this study: lambda protein phosphatase (New England Biolabs, P0753S), animal-free recombinant human EGF (PeproTech, AF-100–15), insulin from bovine pancreas (Merck, I-1882), CaMKII inhibitor RA306 (custom synthesized by Reagency, RGNCY-0117, 1 μM final), PKA Inhibitor 14 to 22 Amide, Cell-Permeable, Myristoylated (Calbiochem, 476,485, 10 μM final), DMSO (Sigma, d8418, 0.1% final), and MedChemExpress-sourced Akt inhibitor MK-2206 dihydrochloride (HY-10358, 100 nM final) and trametinib (HY-10999, 10 nM final).

    Techniques: Phospho-proteomics, Western Blot, Control, Inhibition, Derivative Assay, Knockdown